Resource Logo
FDA News

Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination




 

Food and Drug Administration - August 10, 2011

On August 10, 2011, FDA approved Complera(TM), a fixed dose combination (FDC) drug product containing emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF) for the treatment of HIV. The recommended dose of Complera(TM) is one tablet, containing 200mg/25mg/300mg of FTC/RPV/TDF, once daily, taken orally with a meal.



 


Copyright © 2011 -FDA News, Publisher. All rights reserved to Food and Drug (FDA) Administration FDA.

Information in this article was accurate in August 10, 2011. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.